CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 173 enrolled
Drug / intervention
JTA-004 intra-articular injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02740231
NCT02740231Phase 3Completed

A Two-stage 6-month Multicentre, Randomised, Double-blind, Controlled Study on the Safety and Efficacy Intra-articular Administration of JTA-004 in Patients With Symptomatic Knee Osteoarthritis

Bone Therapeutics S.A·interventional·Posted Apr 15, 2016·Updated Dec 6, 2021

In Brief

A Phase 3 clinical trial evaluating JTA-004 intra-articular injection and Reference product intra-articular injection for Knee Osteoarthritis. Completed, enrolled 173 participants.

Detailed Summary

Osteoarthritis (OA) is the most common joint disease affecting millions of people around the world, for which there is unfortunately no cure. Among existing therapies, viscosupplementation, i.e., the injection of hyaluronic acid into the joint, has an established place in the symptomatic treatment of knee OA. The present Phase IIb/III aiming to assess the safety and efficacy of JTA-004 is organized in two phases. With results obtained in the first phase the best dose of JTA-004 is determined, and the efficacy of the selected dose will then be confirmed in the second phase.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 15, 2016
Enrollment StartFeb 1, 2016
Primary CompletionApr 27, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.2 years ago

Interventions

JTA-004 intra-articular injectiondrug

Each patient will undergo a single injection of JTA-004 into the knee joint

Reference product intra-articular injectiondevice

Each patient will undergo a single injection of Reference product into the knee joint